GlassScriptPhysician profile
Prasad Ancha
NPI 1659313120
$401.88
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $191 · 2021: $102.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $75.78 | 2020 | |
| Ucb, INC. | $61.13 | 2019-2021 | |
| Biogen, INC. | $54.69 | 2020-2021 | |
| Neurelis, INC. | $28.06 | 2020 | |
| Ge Healthcare | $22.93 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.64 | 2020 | |
| Alexion Pharmaceuticals, INC. | $21.30 | 2019 | |
| Genzyme Corporation | $20.97 | 2021 | |
| Horizon Therapeutics Plc | $19.91 | 2019 | |
| Abbvie INC. | $19.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.83 | 2020 | |
| Tanabe Pharma America, INC. | $14.68 | 2020 | |
| Life Molecular Imaging LTD | $13.29 | 2019 | |
| Amgen INC. | $12.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasad Ancha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.